GLP-1 Daily: Ozempic & Wegovy News
FDA Adds Rare Vision-Loss Warning to Every GLP-1 Label
Tuesday, November 10, 2026 · 6 min
The FDA is requiring all approved GLP-1 drugs, including Wegovy, Ozempic, Zepbound and Mounjaro, to warn of a possible increased risk of the rare eye condition NAION. Also: survodutide clears a heart-safety trial, and a Cureus study finds Medicaid obesity-coverage cuts erased most reimbursed GLP-1 dispensing.
Listen
Show notes
The FDA is requiring all approved GLP-1 drugs, including Wegovy, Ozempic, Zepbound and Mounjaro, to warn of a possible increased risk of the rare eye condition NAION. Also: survodutide clears a heart-safety trial, and a Cureus study finds Medicaid obesity-coverage cuts erased most reimbursed GLP-1 dispensing.
In this episode
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease - BioSpace — Gabrielle Masson
“The class-wide label change will involve adding a mention of non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that causes optic nerve swelling and can lead to blindness, often in one eye. With cases of NAION reported for all currently marketed…”
- Survodutide does not raise CV risk in patients with obesity — Erik Swain
“However, this was not a trial that studied survodutide for superiority, so we cannot tell patients that this is going to improve their CV risk.”
- Medicaid GLP-1 Obesity Coverage Cuts Erased 84.7% of Dispensing, Study Finds - PeptideDDP — Peptideddp
“A quasi-experimental study published in Cureus on November 6, 2026, reports that when five state Medicaid programs withdrew coverage of GLP-1 receptor agonists for obesity in late 2025 and January 2026, reimbursed dispensing of obesity-indicated GLP-1 drugs fell 84.7% relative…”